OncoMatch/Clinical Trials/NCT05319314
GCC19CART for Patients With Metastatic Colorectal Cancer
Is NCT05319314 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies GCC19CART for colorectal cancer.
Treatment: GCC19CART — Study ICT-GCC19CART-US-001 (CARAPIA-1) is a Phase 1 study evaluating the safety, tolerability, clinical activity, pharmacokinetics and pharmacodynamics of GCC19CART in subjects with relapsed or refractory metastatic colorectal cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: GUCY2C overexpression (positive by IHC)
Guanylate Cyclase (GCC) positive disease as determined by immunohistochemistry (IHC). Positivity on staining of archival tumor tissue is adequate.
Required: KRAS wild-type
if RAS wild-type an anti-epidermal growth factor receptor (anti-EGFR) therapy in a manner consistent with National Comprehensive Cancer Network (NCCN) guidelines
Required: NRAS wild-type
if RAS wild-type an anti-epidermal growth factor receptor (anti-EGFR) therapy in a manner consistent with National Comprehensive Cancer Network (NCCN) guidelines
Disease stage
Metastatic disease required
Prior therapy
Must have received: fluoropyrimidine-based chemotherapy — advanced or metastatic
Received prior therapy with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy in the advanced or metastatic setting
Must have received: oxaliplatin-based chemotherapy — advanced or metastatic
Received prior therapy with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy in the advanced or metastatic setting
Must have received: irinotecan-based chemotherapy — advanced or metastatic
Received prior therapy with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy in the advanced or metastatic setting
Must have received: anti-vascular endothelial growth factor (anti-VEGF) biological therapy — advanced or metastatic
an anti-vascular endothelial growth factor (anti-VEGF) biological therapy if not contraindicated
Must have received: anti-EGFR therapy — advanced or metastatic
if RAS wild-type an anti-epidermal growth factor receptor (anti-EGFR) therapy in a manner consistent with National Comprehensive Cancer Network (NCCN) guidelines
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Comprehensive Cancer Center · Duarte, California
- University of California San Francisco Medical Center · San Francisco, California
- University of Colorado Hospital - Anschutz Cancer Pavilion · Aurora, Colorado
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify